FibroGen, Inc

Good day and welcome to the FibroGen third quarter 2024 earnings conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. If you withdraw your question, please press star then two. Please note this event is being recorded. I would now like to hand the call over to David DeLucia, Vice President of Investor Relations. Please go ahead.

Good afternoon, everyone.

Thank you for joining today to discuss our third quarter 2024 financial and business results. I'm David DeLucia, Vice President of Corporate FP&A and Investor Relations at Fiverr Jones. Joining me on today's call are Thayne Weddick, our Chief Executive Officer, Juan Graham, our Chief Financial Officer, and Chris Chung, our Senior Vice President of China Operations. Following our prepared remarks, we will open the call to your questions. I would like to remind you that remarks made on today's call include forward-looking statements about FibroGem. Such statements may include, but are not limited to, our collaborations with AstraZeneca and Astellas, financial guidance, the initiation, enrollment, design, conduct, and results of clinical trials, our regulatory strategies and potential regulatory results, our research and development activities, commercial results and results of operations, risks related to our business, and certain other business matters. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in that statement. A more complete description of these and other material risks can be found in Fibrogen's filings with the SEC, including our most recent Form 10-K and Form 10-Q. Fibrogen does not undertake any obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise. The press release reporting our financial results and business update and a webcast of today's conference call can be found on the Investors section of Fibrogen's website at www.fibrogen.com. With that, I would like to turn the call over to our CEO, Dane Weddick.

Thank you, Dave. Good afternoon, everyone, and welcome to our third quarter 2024 earnings call. On today's call, I will highlight our current strategy for the company and the exciting opportunity for FG3246 and FG3180, our first-in-class antibody drug conjugate targeting TD46, and our PET imaging agent in metastatic castration-resistant prostate cancer. I will also highlight the continued strong performance of Roxidustat in China and the potential for Roxidustat development for the treatment of anemia due to lower-risk mild dysplastic syndrome. Then, Juan Graham, our CFO, will review the financials, after which we will open the call for your questions. On slide three, I would like to highlight the strategic pillars for our company. First, Advancing FG-3246 and FG-3180 and MCRPC remains a key priority. In the second quarter of this year, we shared important data from two phase one studies highlighting the potential of FG-3246 as both monotherapy and in combination with enzalutamide. I'll provide a more detailed overview of where we are with the program and the upcoming 2025 catalysts in a moment. Second, ROXDU-STAT continues to demonstrate very strong performance in China, generating significant net revenue and positive cash flow with robust year-over-year revenue and volume growth. Thanks to this impressive performance, we are reiterating our guidance of Fibrogen's full-year net product revenue under U.S. GAAP to be between $135 and $150 million and raising the bottom end of our full-year guidance for ROXDU-STAT net sales in China to $330 to $350 million. In addition, we anticipate an approval decision from the China authorities in early 2025 for chemotherapy-induced anemia, which, if approved, would represent a meaningful growth opportunity on top of the substantial revenue generated by Roxadustat in anemia associated with chronic kidney disease. If approved, VibraGen will receive a $10 million milestone payment from our China partner, AstraZeneca. Third, we have a number of partnering opportunities for our remaining pipeline. Regaining the rights to Roxidustat from AstraZeneca in the U.S. and ROW, excluding China and South Korea, enables us to pursue internal or external development of certain indications with high unmet need, such as anemia in patients with lower-risk myelodysplastic syndromes. Moreover, we continue to seek partnership opportunities for our early oncology pipeline of the Phase I-ready FG3165, an anticolectin-9 antibody, and FG-3175, an anti-CCR8 antibody. Lastly, due to our significant U.S. cost reduction efforts and the wind down of the Pamrevelmab development program, FibroGen exited the third quarter in a solid cash position with $160 million in cash, cash equivalents, and accounts receivable. Assuming additional repatriation of cash from our China operations, we expect our cash, cash equivalents, and accounts receivable to fund operating plans into 2026. Altogether, we are confident that our refined focus, along with our strong foundation, position us well to create value for shareholders now and in the future. I will now provide a brief overview of our FG3246 and FG3180 programs in MCRPC. Slide five highlights the high unmet need in late-stage prostate cancer. There are approximately 290,000 men diagnosed with prostate cancer each year in the U.S., Of these, there are 65,000 drug-treatable patients where the cancer is metastasized and become castrate-resistant, resulting in a grim five-year survival rate of approximately 30%. There remains a significant opportunity for new treatments that can extend survival for these men. FG3246 could be this new treatment option. Turning to slide six, FG3246 is a potential first-in-class ADC in development for MCRPC patients. with a novel antibody, YS5, which binds to a tumor-selective epitope of CD46. CD46 and the specific CD46 epitope have several distinguishing features. CD46 is upregulated during tumorigenesis and helps tumors evade complement-dependent cytotoxicity. The CD46 epitope is highly expressed in MCRPC tissues with lower interpatient variability and higher median expression compared with PSMA as depicted in the graph in the lower right-hand portion of the slide. This expression is upregulated in the progression from localized castration-sensitive prostate cancer to metastatic castration-resistant prostate cancer and further overexpressed following treatment with androgen signaling inhibitors. And the CD46 epitope is also overexpressed in colorectal cancer and other solid tumors. A companion PET imaging agent, FG3180, utilizes the same targeting antibody as FG3246, and is also under clinical development. In preclinical studies, the PET imaging agent has demonstrated specific targeting of and uptake by CD46-positive tumor cells. Slide 7 highlights the importance of the companion PET imaging agent, FG3180, to the development pathway for FG3246. We believe that having a patient selection biomarker would not only allow us to better enrich the patient population in the phase three portion of the clinical development program, it would also enable differentiation of FG3246 in the prostate cancer treatment landscape. In addition, FG3180 could represent an important commercial opportunity as a companion diagnostic to FG3246. Slide eight recaps the top line results from the phase one monotherapy study. and the Phase 1B portion of the investigator-sponsored study of FG3246 in combination with enzalutamide, both of which were reported in the second quarter of 2024. The completed monotherapy study included a total of 56 MCRPC patients who were biomarker unselected and were heavily pretreated, receiving a median of five lines of therapy prior to FG3246. In the efficacy of valuable population of 40 patients, we observed a median radiographic progression-free survival of 8.7 months, overall response rate of 20% confirmed by RESIST 1.1, and PSA reductions of greater than 50% in 36% of patients. Adverse events were consistent with those observed with other MMAE-based ADC therapies. The manuscript describing the phase one monotherapy trial has been submitted, and we anticipate acceptance and publication in the coming months. Following our recent discussion with the FDA regarding the FG3246 development program, we are preparing to initiate the Phase II monotherapy trial of FG3246 in the first quarter of 2025. Interim results of the Phase Ib portion of the investigator-sponsored combination study with enzalutamide that is currently being conducted at UCSF were reported at ASCO in June of this year. These interim results included data on 17 biomarker unselected patients, 70% of which were pretreated with at least two prior ARSIs. In addition to establishing the phase two dose of FG3246, the IST also demonstrated an encouraging preliminary estimate of RPFS of 10.2 months, with PSA declines observed in 71% of evaluable patients. The trial remains on track for top line results in the first half of 2025, and will also include CD46 expression data on patients screened with FG3180, our PET biomarker, during the Phase II portion of the IST. On slide 9, we depict a comparison of the initial results from the monotherapy trial in heavily pretreated patients and the combination trial that show an impressive RPFS versus the existing FDA-approved standard of care in the MCRPC setting. While we cannot make direct comparisons to these trials, Due to differences in things such as study design and previous treatments, we are encouraged by these RPFS results. Moving to slide 10, we would like to share the phase two dose optimization trial design based on our discussion with the FDA. We plan to enroll 75 patients across three dose levels to determine the optimal dose for phase three based on efficacy, safety, and PK parameters. It is important to note that FG3180 will also be a part of the study as we seek to demonstrate the correlation between CD46 expression and response to the ADC in this all-comers population. One other important design element is the primary prophylaxis with GCSF to mitigate adverse events associated with neutropenia, commonly seen with ADCs containing an MMAE payload. The addition of GCSF may enable a better tolerated and more consistent treatment, thereby extending duration of therapy with FG3246 and potentially enhancing efficacy measures, such as RPFS. On slide 11, we highlight the recent and ongoing studies for FG3246 and FG3180. As I mentioned earlier, we are expecting additional data for FG3180, our PET imaging agent, for multiple studies being run at UCSF, including the Phase I imaging development study, which was recently upsized, as well as the combination trial with enzalutamide. Slide 12 shows the recent and upcoming catalysts for the FG3246 program. As mentioned earlier, we had a productive meeting with the FDA regarding the FG3246 development pathway and received guidance for the Phase II trial design highlighted a few slides earlier. In addition, IND submissions for FG3246 and FG3180 are planned this quarter and next quarter respectively. We have potential value inflection points in the near term with the anticipated initiation of the phase two dose optimization study in MCRPC in the first quarter of 2025, and the top line results from the phase two portion of the combination study with enzalutamide, which are expected in the first half of 2025. To summarize on slide 13, FG3246 targets a novel epitome on prostate cancer cells with first-in-class potential. It has already demonstrated promising efficacy signals with an acceptable safety profile both in monotherapy and combination settings. We are excited for the upcoming milestones and look forward to updating you on the program as the studies progress. Moving now to slide 15, Roxidustat for anemia of chronic kidney disease continues its robust performance in China. Third quarter total Roxidustat net sales in China by Fibrogen and the distribution entity jointly owned by Fibrogen and AstraZeneca total $96.6 million. compared to $77.1 million in the third quarter of 2023, an increase of 25%, driven by an increase in volume of 34%. Fibrogen's portion of ROX-induced net product revenue in China was $46.2 million for the third quarter on a US GAAP basis, compared to $29.4 million in the third quarter of 2023, an increase of 57%. Moving to slide 16. Roxadustat continued its category leadership and brand value share in China, maintaining a 45% share in the most recent three-month period ending in August of 2024. The potential approval of the chemotherapy-induced anemia indication early next year would provide an important new treatment alternative for patients with CIA, be a meaningful addition to the Roxadustat business in China, and would trigger a $10 million milestone payment from AstraZeneca. Given that there have been several generic applications filed and two applications approved in China, I would like to reiterate that the impact of a generic approval and launch in China is meaningfully different than in the U.S. Generic players face lead time and execution risks of market adoption after approval, as they need to be admitted into individual hospital formularies one listing at a time. Therefore, originator products do not experience a meaningful deterioration in revenue until they are subjected to volume-based purchasing. which only occurs after at least four generic products are approved, and the government includes the originator in the BBP process. Even then, originator products in China have historically maintained a stream of net product revenues and profits after generics enter the market. Despite the expiration of our composition of matter patents in June of this year, we do not expect meaningful deterioration of the Rocksteer Step business in the near term. In addition to the exceptional performance of roxidustat in China this quarter, roxidustat penetration in Europe continues to increase, showing quarter-over-quarter growth. We expect this growth to continue given the fact that roxidustat is reimbursed in all EU five countries, is the only hip PHI indicated in the EU for the treatment of anemia of CKD in both non-dialysis and dialysis patients, and has exclusivity until 2036, positioning it for continued growth and HIP market leadership over the next decade plus. Now to slide 17, we announced earlier this year that we regained all U.S. and ROW ROXADUSTAT rights from AstraZeneca with the exception of South Korea while the China collaboration agreement remains in place. Regaining the rights to ROXADUSTAT in the U.S. allows us to pursue ROXADUSTAT development opportunities with potential partners or on our own in indications such as anemia associated with lower risk myelodysplastic syndromes. Slide 18 highlights the unmet need and the potential for Roxidustat in patients with anemia associated with lower risk MDS. There is a lack of effective second line and beyond treatments given the currently available therapies are effective in approximately 50% of patients. In addition, there are no oral options available or in late stage development, which could be a meaningful differentiator for Roxidustat and potentially translate into significant commercial opportunity. Moving on to slide 19. In late 2023, subgroup analysis from the Phase III Matterhorn study of Roxidustat in patients with anemia of lower-risk MDS were presented at the American Society of Hematology annual meeting. In patients with anemia associated with lower-risk MDS who entered the trial with a higher transfusion burden, Roxidustat demonstrated a meaningful difference in transfusion independence versus placebo, results that are highly similar to the pivotal trials for two recently approved therapies for anemia associated with lower-risk MDS. Based on these results, we believe that Roxidustat represents an important potential therapy for patients with anemia associated with lower-risk MDS. Therefore, we are currently evaluating options for Roxidustat to determine the best path for continued development with the aim of realizing an additional value for Roxidustat in this high-value indication. I will now turn the call over to Juan to discuss the company's financials. Juan?

Thank you, Payne. I will focus my remarks with a revenue summary for the third quarter of 2024, subsequently providing financial performance details of our China business for the quarter. And finally, I will wrap up with operating expense results and our cash outlook. I also want to remind everyone that more information on our financial results is available in our press release and our recently filed PENQ. For the third quarter of 2024, Total revenue was $46.3 million compared to $40.1 million for the same period in 2023, an increase of 15% year-over-year. We recorded $46.2 million of net product revenue for Ruxa-Dustat sales in China compared to $29.4 million in the third quarter of 2023, representing an increase of 57% year-over-year. In Q3 2024, we recorded $0.4 million in development revenue compared to $6.8 million during the third quarter of 2023. As mentioned in prior quarters, after the termination of the AstraZeneca-US Rest of the World Agreement, we expect quarterly development revenue to be below half a million dollars for the remainder of 2024. In Q3 2024, we recorded negative $0.3 million of direct product revenue compared to $1.3 million during the third quarter of 2023. We recognized $1.1 million from our Estella's royalties in the EU, and at the same time, we recorded a $1.4 million true-up from our Estella's royalties in Japan due to product mix. Now, moving on to our financial performance in China. Total Ruxidustat net sales from the Joint Distribution Entity, or JDE, owned by AstraZeneca and FibroGen and direct-to-distributor sales for FibroGen, was $96.6 million in the third quarter compared to $77.1 million in the third quarter of 2023, an increase of 25% year-over-year. This growth has enabled us to achieve and maintain a brand value share of 45% of the category in China. From total Roxidusta net sales in China, FiberGen's net transfer price from sales to the JDE was $29.7 million this quarter compared to $24.2 million in the third quarter of 2023, an increase of 23% year-over-year. Net transfer price is the best reflection of FibreGen's portion of the cash received from Ruxudustat in China. During this quarter, we also released $12.5 million from deferred revenue due primarily to changes in forward-looking expectations for Ruxudustat in China. As a result, FibreGen recorded $42.2 million in net revenue for the quarter from Ruxudustat sales to the JDE and $4 million of direct-to-distributor sales for FibreGen China, totaling $46.2 million in the U.S. gap year. For full year 2024, four-year models, we reiterate our forecast for FiberGen China net product revenue to be between $135 to $150 million on the U.S. GAAP basis. FiberGen China revenue assumes a forecast of Ruxudus.net sales in China to range from $330 to $350 million, narrowing our prior guidance of $320 to $350 million. Now moving down the income statement. Total operating costs and expenses for the third quarter of 2024 were $63.1 million compared to $103.6 million for the third quarter of 2023, a decrease of $40.5 million or 39% year-over-year, excluding restructuring charges of $18.6 million in the third quarter. Our total operating costs and expenses were $44.5 million. Total operating costs and expenses for the quarter came in below our guidance range of $45 to $55 million, which reflects a strong execution and cost reduction in discipline spend. R&D expenses for the third quarter of 2024 were $21.7 million compared to $61.2 million in the third quarter of 2023, a decrease of 65% or $39.5 million year over year. Of our $21.7 million of R&D expenses, Approximately 42% was related to Pamrelumab, 37% directed to FG-3246, with the remainder directed towards Ruxodustat and our immuno-oncology acid development activities. We expect our Pamrelumab and immuno-oncology R&D expenses to decline significantly in the fourth quarter of the year, as we have either shut down or reprioritized our R&D spend. SG&A expenses for the third quarter of 2024 were $17.6 million compared to $25.6 million in the third quarter of 2023, a decrease of 31% or $8 million year-over-year, primarily driven by the company's cost reduction efforts. Finally, cost of goods sold for the third quarter of 2024 was $5.3 million compared to $4.2 million for the third quarter of 2023. During the third quarter of 2024, we recorded a net loss of $17.1 million or 17 cents net loss for both basic and diluted share as compared to a net loss of $63.6 million or 65 cents per basic and diluted share for the third quarter of 2023. As we have previously stated, We initiated a significant cost reduction plan to enable our focus on FG-3246, FG-3180, and ROC's reduced debt assets. We have reduced our headcount by approximately 72% in the US. We have moved to a virtual work environment after terminating our lease and substantially reduced our operating costs to maximize our cash. With this backdrop, We expect our total operating costs and expenses, including cost of goods sold in the fourth quarter, to be between $35 million and $40 million, which includes $1 to $2 million in restructuring charges in the fourth quarter. Now shifting towards cash, as of September 30th, we reported $160 million in cash, cash equivalents, and accounts receivables. This reflects an increase of $12.9 million quarter-over-quarter. To provide further clarity on our cash balance, in the third quarter, we have invoiced and collected from AstraZeneca $27.7 million for certain historical R&D expenses and milestones owed to FibreGen. Going forward, we expect to have additional cash collections in the fourth quarter of 2024 and the first quarter of 2025. These collections will be offset through payments for historical co-promotion sales and marketing expenses due to AstraZeneca China. The timing of these payments will be in the fourth quarter of 2024 and the first quarter of 2025. After considering the payments to and from AstraZeneca over the coming quarters, The result will be in a net cash collection of roughly $0.5 million. For the third quarter, if we exclude the above-mentioned cash inflows, our net operating cash form was $14.8 million during the quarter. We have consistently stated our cash balance will enable us to fund our operating plan into 2026. Assuming additional repatriation of cash from our China operations, which we continuously assess through multiple avenues, we expect our cash, cash equivalents, and accounts receivable to fund upgrading plans into 2026. Thank you, and now I will turn the call back over to Faith.

Thank you, Juan. To conclude, we remain excited about the company's positive outlook and the potential value we can create for stakeholders. Rocks Do Set continues to perform extremely well in China, where we expect an approval decision of our SMDA for the chemotherapy-induced anemia indication early next year. And our partner, Astellas, continues with the commercialization of Roxadustat in Europe, Japan, and other markets. Aiming to enhance Roxadustat's value to FibroGen, we are actively exploring development in anemia in patients with lower-risk MDS, either by ourselves or through partnership discussions. Our oncology pipeline of FG3246 and FG3180 And MCRPC continues to advance after showing compelling top-line data in the Phase I monotherapy study and in the interim data from the Phase Ib dose escalation portion of the investigator-sponsored study of FG3246 in combination with enzalutamide. We look forward to the publication of the Phase I monotherapy data in the coming months, the anticipated initiation of the Phase II monotherapy dose optimization study in the first quarter of 2025, and the top-line results from the Phase II portion of the combination IST in the first half of 2025. In summary, we will continue to execute on our current strategic priorities as a leaner and more focused organization, as we continue to strive towards evaluation that we believe is more reflective of our current and future Rocks to Do Set revenue stream, first-in-class phase two ready ADC and companion PET imaging agent, and our strong balance sheet.

I will now turn the call over to the operator for Q&A.

We will now begin the question and answer session. To ask a question, you may press star then 1 on your telephone keypad. If you are using a speakerphone, please pick up your handset before pressing the key. To withdraw your question, please press star then 2. At this time, we will pause momentarily to assemble the roster.

And our first question will come from Andy Heisch of William Blair.

Please go ahead.

Thanks for taking our question, Juan. Hopefully you're feeling okay there. So in terms of the investigator-sponsored study, the Phase 2 portion, would it be the Stage 1-9 patients followed by the 15-patient Stage 2 in terms of kind of the top line that can be expected first half of next year, just trying to get a sense of how, you know, how you manage your expectations and frame the extent of the release of data.

Yeah, thanks, Andy, for your question. This is Thane. Yeah, so I think that we should expect in the top line results for the IST, for the combination with enzalutamide, to include not only obviously the patients from the escalation cohort, but also RPFS data from the expansion cohort, which is dosed at 2.1 mgs per K along with 160 milligrams per day of enzalutamide. And so we have to wait for Rahul Agarwal, who is the sponsor of the IST, to confirm exactly what data will be available when. In other words, as patients are enrolled, we'll see six months RPFS data on some, but maybe not six months on others. And then as the trial continues to dose patients, then the patients who had a six-month RPFS then will have further RPFS readings. And then those that didn't quite have a six-month RPFS will then progress to a six-month data point. So it will mature over time. But our best guidance at this point in time is that in the first half of next year that we should expect top line results on both the escalation cohort and the expansion cohort, roughly 36 patients in total.

That's helpful. Thank you. And maybe just a bit on the PET imaging agent. So, obviously, the standard of care now is basically you get, you know, either gallium-based or fullerene-based agent infused. Thirty minutes later, you get an image. I'm just curious if that is similar to the circonium-89. You know, how long do patients typically have to wait to get a PET image made? So, just basically kind of on the logistical side of things.

Yeah, so that's what's being explored right now, Andy, as part of the ongoing work at UCSF with the PET imaging agent. The expectation isn't that it will be, you know, minutes. It will be days post-exposure to the PET imaging agent. The work in the coming, you know, months ahead of the Phase II start will determine exactly the number of days, but it won't be 30 minutes ahead and then you administer the first dose of of the ADC, it will likely be, let's say, you know, six days or so.

Got it. That's helpful. Thank you so much. The next question comes from Paul Choi of Goldman Sachs.

Please go ahead.

Hi, Thayne and team. This is Khalil calling in for Paul. Thank you so much for taking our questions. I guess a couple quick ones from us. Quickly, I guess on FG33. Sorry, on the phase two that you're planning to initiate next quarter, or I suppose the Q1 of 25, I think you mentioned 75 patients earlier in this call. I just wanted to clarify, will all of those be imaged as well with FG3180? And then I had a quick follow-up on Roxaducet after that.

Yeah, thanks, Khalil. The majority of them will be treated with the imaging agents at the outset of therapy, followed by then treatment with the ADC. Not all 75 of them, and that's because You know, we'll be filing the IND for FG3246 this quarter, and we'll file the IND for the PET imaging agent next quarter. So we won't have the PET imaging agent ready exactly when the first patient is expected to be dosed in the monotherapy trial, but it won't be too long after that when we will start treating patients with the PET imaging agent. So the expectation is the majority of them, of the 75, will receive the PET imaging agent.

Got it. Okay, that makes sense. And then my quick follow-up on Roxaducet was – Just on guidance, I think the midpoint of your China sales sort of imply continued growth into the fourth quarter of ROX at Doostat. But then the net sales variance you gave of 135 to 150, the high end of that guidance implies a very modest year-over-year decline in the fourth quarter. I may have missed this earlier, but Juan, if you're still on the line, I think you mentioned the $12.5 million release from the JDE. If you could just touch on that again and just Explain what's driving the decrease sequentially that this guidance is implying in the fourth quarter. That'd be really helpful for us.

Yeah, Khalil, good question. And thank you for bearing with me there for my remarks with a little bit of the end of a cold here that I'm having. What I'm basically alluding to your question is The 135 to 150 still somewhat contemplate that a potential approval of the CIA Indication if that were to happen the way that you know our single performance obligation model basically Elucidates that we would need to accrue further into deferred revenue given the future expected performance of the asset from an accounting perspective, so In that sense, our sales would basically, our sales guidance would have that into consideration as we are providing you this perspective at this point in time. We will see over the course of the remainder of the year if we have that approval or not. If the CIA indication flows into 2025, then we may be on the higher end of the spectrum here.

Okay, cool. I'm so sorry, but just to clarify, you mentioned, I may have misheard, but did you mention a $12.5 million change in the deferred revenue? Was that an increase or a decrease? I think I missed that earlier in the call.

That's an increase to this quarter's revenue, and it's basically a release of our deferred revenue. However, the way that the single performance obligation model operates is that if, for instance, we get a CIA approval, and an enhancement of our future revenue, we would need to defer more revenue and therefore reduce our revenue for that specific quarter. So that's kind of like the dynamic of how our single performance obligation model works, that if we have future expected revenue that is above and beyond to what we're currently expecting, then this quarter or the quarter under which that happens, we will need to accrue further into our deferred revenue on the expectation of that future revenue curve.

Understood. Okay, that makes sense. Thank you so much, and I hope you feel better.

Appreciate the time. Thank you. Thank you. Thanks, Khalil. This concludes our question and answer session.

I'd like to turn the call over to Tane Reddick for any closing remarks.

So thank you for joining us today for today's third quarter earnings call and for your continued interest in Fibergen. Enjoy the rest of your day.

Thanks, everyone. The conference is now concluded. Thank you for attending today's presentation, and you may now disconnect.